MX2022011407A - Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda. - Google Patents
Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda.Info
- Publication number
- MX2022011407A MX2022011407A MX2022011407A MX2022011407A MX2022011407A MX 2022011407 A MX2022011407 A MX 2022011407A MX 2022011407 A MX2022011407 A MX 2022011407A MX 2022011407 A MX2022011407 A MX 2022011407A MX 2022011407 A MX2022011407 A MX 2022011407A
- Authority
- MX
- Mexico
- Prior art keywords
- myeloid leukemia
- acute myeloid
- compounds
- treating
- inhibiting recurrence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/079464 WO2021184154A1 (en) | 2020-03-16 | 2020-03-16 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| PCT/US2021/022322 WO2021188417A1 (en) | 2020-03-16 | 2021-03-15 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011407A true MX2022011407A (es) | 2022-10-13 |
Family
ID=77767943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011407A MX2022011407A (es) | 2020-03-16 | 2021-03-15 | Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11963960B2 (enExample) |
| EP (1) | EP4121430A4 (enExample) |
| JP (1) | JP7744358B2 (enExample) |
| KR (1) | KR20220154164A (enExample) |
| CN (1) | CN115298180B (enExample) |
| AR (1) | AR121570A1 (enExample) |
| AU (2) | AU2020436612A1 (enExample) |
| BR (1) | BR112022018345A2 (enExample) |
| CA (1) | CA3168988A1 (enExample) |
| IL (1) | IL296296A (enExample) |
| MX (1) | MX2022011407A (enExample) |
| PE (1) | PE20230461A1 (enExample) |
| PH (1) | PH12022552169A1 (enExample) |
| TW (1) | TWI899184B (enExample) |
| WO (2) | WO2021184154A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| RS65962B1 (sr) | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| EP4161933A1 (en) * | 2020-06-08 | 2023-04-12 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| CN114075190A (zh) * | 2020-08-20 | 2022-02-22 | 北京诺诚健华医药科技有限公司 | 杂环类btk抑制剂 |
| CN113861179A (zh) * | 2021-10-22 | 2021-12-31 | 上海应用技术大学 | 一种新型flt3激酶抑制剂及其合成与应用 |
| WO2025124429A1 (zh) * | 2023-12-11 | 2025-06-19 | 北京康辰药业股份有限公司 | 芳香胺化合物及其药物组合物、应用 |
| CN121039131A (zh) * | 2024-01-11 | 2025-11-28 | 佩勒梅德有限公司 | 新型吡咯并三嗪衍生物及其用途 |
| KR20250157634A (ko) | 2024-04-29 | 2025-11-05 | 대한민국(질병관리청 국립보건연구원장) | Bax 활성제를 유효성분으로 포함하는 항-hiv-1 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199902301T2 (xx) * | 1997-03-19 | 1999-12-21 | Basf Aktiengesellschaft | Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�. |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| ID29028A (id) * | 1998-09-18 | 2001-07-26 | Basf Ag | Pirolopirimidina sebagai penghambat protein kinase |
| US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| JP2003509428A (ja) * | 1999-09-17 | 2003-03-11 | アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー | 治療薬としてのピラゾロピリミジン |
| MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| WO2007064931A2 (en) * | 2005-12-02 | 2007-06-07 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| ES2545907T3 (es) * | 2005-12-29 | 2015-09-16 | Abbvie Inc. | Inhibidores de proteína quinasa |
| SG10202107066WA (en) * | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| ES2396613T3 (es) * | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
| JP6327713B2 (ja) * | 2012-07-27 | 2018-05-23 | 国立研究開発法人理化学研究所 | 急性骨髄性白血病の治療又は再発抑制剤 |
| USRE48175E1 (en) * | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| WO2016019237A2 (en) * | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| US10266535B2 (en) * | 2015-01-21 | 2019-04-23 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Inhibitor of FLT3 kinase and use thereof |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| JP2019529423A (ja) * | 2016-09-15 | 2019-10-17 | 国立研究開発法人理化学研究所 | 急性骨髄性白血病を処置するためのＨＣＫ阻害剤及びＢｃｌ−２阻害剤 |
| CN113544130B (zh) | 2019-05-31 | 2024-01-09 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| AU2020301399B2 (en) * | 2019-06-24 | 2025-12-18 | Dana-Farber Cancer Institute, Inc. | HCK degraders and uses thereof |
| KR20220098732A (ko) * | 2019-10-08 | 2022-07-12 | 다나-파버 캔서 인스티튜트 인크. | 요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체 |
| MX2022008148A (es) * | 2020-01-02 | 2022-07-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidores de btk. |
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
-
2020
- 2020-03-16 AU AU2020436612A patent/AU2020436612A1/en active Pending
- 2020-03-16 WO PCT/CN2020/079464 patent/WO2021184154A1/en not_active Ceased
-
2021
- 2021-03-12 AR ARP210100645A patent/AR121570A1/es not_active Application Discontinuation
- 2021-03-15 AU AU2021239828A patent/AU2021239828B2/en active Active
- 2021-03-15 KR KR1020227035324A patent/KR20220154164A/ko active Pending
- 2021-03-15 JP JP2022555625A patent/JP7744358B2/ja active Active
- 2021-03-15 PH PH1/2022/552169A patent/PH12022552169A1/en unknown
- 2021-03-15 MX MX2022011407A patent/MX2022011407A/es unknown
- 2021-03-15 PE PE2022001990A patent/PE20230461A1/es unknown
- 2021-03-15 US US17/201,827 patent/US11963960B2/en active Active
- 2021-03-15 BR BR112022018345A patent/BR112022018345A2/pt not_active Application Discontinuation
- 2021-03-15 IL IL296296A patent/IL296296A/en unknown
- 2021-03-15 EP EP21772015.0A patent/EP4121430A4/en active Pending
- 2021-03-15 WO PCT/US2021/022322 patent/WO2021188417A1/en not_active Ceased
- 2021-03-15 CN CN202180016180.0A patent/CN115298180B/zh active Active
- 2021-03-15 CA CA3168988A patent/CA3168988A1/en active Pending
- 2021-03-16 TW TW110109254A patent/TWI899184B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220154164A (ko) | 2022-11-21 |
| EP4121430A1 (en) | 2023-01-25 |
| AR121570A1 (es) | 2022-06-15 |
| TWI899184B (zh) | 2025-10-01 |
| WO2021184154A1 (en) | 2021-09-23 |
| JP2023518035A (ja) | 2023-04-27 |
| CA3168988A1 (en) | 2021-09-23 |
| PE20230461A1 (es) | 2023-03-14 |
| IL296296A (en) | 2022-11-01 |
| AU2021239828B2 (en) | 2025-06-26 |
| AU2021239828A1 (en) | 2025-04-03 |
| BR112022018345A2 (pt) | 2022-11-08 |
| WO2021188417A1 (en) | 2021-09-23 |
| US11963960B2 (en) | 2024-04-23 |
| CN115298180B (zh) | 2025-06-10 |
| US20210299128A1 (en) | 2021-09-30 |
| JP7744358B2 (ja) | 2025-09-25 |
| PH12022552169A1 (en) | 2024-01-29 |
| AU2020436612A1 (en) | 2022-09-01 |
| TW202200583A (zh) | 2022-01-01 |
| EP4121430A4 (en) | 2024-04-17 |
| CN115298180A (zh) | 2022-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552169A1 (en) | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | |
| MY206478A (en) | Inhibitors of sarm1 | |
| MX2025001648A (es) | Inhibidores del oncogen homologo del virus de sarcoma de rata kirsten (kras) | |
| ZA202301801B (en) | Inhibitors of sarm1 | |
| MX2025015502A (es) | Inhibidores del oncogén de sarcoma de rata de kirsten (kras) | |
| MX2023013912A (es) | Metodos para inhibir ras. | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| CR20230057A (es) | Compuestos tríciclicos de urea como inhibidores de jak2 v617f | |
| CR20230103A (es) | Análogos de rapamicina ligados a c40, c28 y c32 como inhibidores de mtor | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| MX2022012329A (es) | Compuestos de pirazolilpropanamida y usos de los mismos para el tratamiento de cáncer de próstata. | |
| MX2024003713A (es) | Usos de moleculas de union al antigeno multiespecificas dirigidas al ligando tipo delta 3 (dll3). | |
| MX2023004373A (es) | Metodos y composiciones para la degradacion dirigida de proteinas. | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| MX2024004993A (es) | Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| EP4674415A3 (en) | Azaquinolines as inhibitors of cd38 | |
| MX2020012291A (es) | Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. | |
| CR20240447A (es) | Compuestos de urea tricíclica como inhibidores de v617f de jak2. | |
| PH12022550497A1 (en) | Perk inhibiting compounds | |
| MX2025007378A (es) | Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2 | |
| EP4691564A3 (en) | Neurokinin inhibitors such as aprepitant for treating non small cell lung carcinoma or breast cancer without mutations | |
| CO2024001405A2 (es) | Composiciones y métodos para el tratamiento de cáncer | |
| MX2022011778A (es) | Construcciones de fusion de dominios liticos, inhibidores de puntos de control y metodos de fabricacion utilizando el mismo. | |
| MX2025000637A (es) | Moleculas de union al antigeno anti-steap1 y sus usos |